THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 119 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,212,089 | +302.1% | 142,935 | +325.3% | 0.00% | – |
Q1 2024 | $301,464 | -92.8% | 33,608 | -91.0% | 0.00% | -100.0% |
Q4 2023 | $4,175,851 | +5.3% | 371,517 | -19.1% | 0.00% | 0.0% |
Q3 2023 | $3,965,580 | -10.1% | 459,511 | +7.8% | 0.00% | 0.0% |
Q2 2023 | $4,413,447 | +231.3% | 426,420 | +247.3% | 0.00% | 0.0% |
Q1 2023 | $1,332,011 | -18.8% | 122,766 | -16.0% | 0.00% | 0.0% |
Q4 2022 | $1,639,848 | -14.9% | 146,154 | -23.1% | 0.00% | 0.0% |
Q3 2022 | $1,926,000 | +145.0% | 189,947 | +119.0% | 0.00% | – |
Q2 2022 | $786,000 | -82.8% | 86,733 | -81.8% | 0.00% | -100.0% |
Q1 2022 | $4,565,000 | +675.0% | 477,434 | +796.3% | 0.00% | – |
Q4 2021 | $589,000 | +450.5% | 53,266 | +268.7% | 0.00% | – |
Q3 2021 | $107,000 | -63.1% | 14,446 | +1.8% | 0.00% | – |
Q1 2021 | $290,000 | -7.3% | 14,192 | -32.9% | 0.00% | – |
Q3 2020 | $313,000 | -98.8% | 21,140 | -98.3% | 0.00% | -100.0% |
Q2 2020 | $25,585,000 | +646.6% | 1,218,912 | +762.5% | 0.02% | +111.1% |
Q1 2018 | $3,427,000 | +1622.1% | 141,329 | +1235.3% | 0.01% | +800.0% |
Q1 2016 | $199,000 | – | 10,584 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Madison Avenue Partners, LP | 8,511,350 | $72,176,248 | 9.12% |
Newtyn Management, LLC | 2,124,703 | $18,017,481 | 3.38% |
Irenic Capital Management LP | 2,760,948 | $23,412,839 | 2.86% |
Weiss Asset Management LP | 7,457,060 | $63,235,869 | 2.39% |
Oasis Management Co Ltd. | 1,157,965 | $9,819,543 | 2.21% |
Park West Asset Management LLC | 1,700,000 | $14,416,000 | 1.06% |
Baupost Group | 4,200,021 | $35,616 | 0.98% |
Camber Capital Management LP | 1,000,000 | $8,480 | 0.24% |
Virtus ETF Advisers LLC | 38,386 | $325,513 | 0.16% |
GSA CAPITAL PARTNERS LLP | 204,089 | $1,731 | 0.12% |